Market Place
Sourcing Support
Bristol Myers Squibb Completes Acquisition of RayzeBio
26 Feb 2024 //
BUSINESSWIRE
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
23 Feb 2024 //
BUSINESSWIRE
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
12 Feb 2024 //
BUSINESSWIRE
BMS beat 2 other pharmas in bid for RayzeBio
25 Jan 2024 //
FIERCE BIOTECH
Bristol Myers to buy RayzeBio for $4.1 billion in targeted cancer therapy push
27 Dec 2023 //
REUTERS
RayzeBio Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
RayzeBio to Participate in Upcoming Investor Conferences in November 2023
06 Nov 2023 //
GLOBENEWSWIRE
RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
01 Nov 2023 //
GLOBENEWSWIRE
FDA selects RayzeBio to Participate in the Inaugural CDRP Program
24 Oct 2023 //
GLOBENEWSWIRE
RayzeBio to Present at European Society for Medical Oncology (ESMO) Congress
18 Oct 2023 //
GLOBENEWSWIRE
RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering
19 Sep 2023 //
BUSINESSWIRE
RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering
14 Sep 2023 //
BUSINESSWIRE
RayzeBio plans IPO to push `pipeline-in-a-product` through ph. 3
25 Aug 2023 //
FIERCE BIOTECH
RayzeBio Announces First Patient Dosed in PIII ACTION-1 Study, Evaluating RYZ101
31 May 2023 //
BUSINESSWIRE
RayzeBio to Present at Upcoming Medical Conferences
22 May 2023 //
BUSINESSWIRE
RayzeBio Nominates Glypican-3 Targeted Radiopharmaceutical Therapy Drug Candidate
21 Mar 2023 //
BUSINESSWIRE
RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101
20 Mar 2023 //
BUSINESSWIRE
RayzeBio to Present at 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
BUSINESSWIRE
RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE)
04 Jan 2023 //
BUSINESSWIRE
RayzeBio Appoints Industry Veteran Rich Heyman as Chairman of Board of Directors
07 Dec 2022 //
BUSINESSWIRE
RayzeBio raises $160m to advance cancer radiopharmaceuticals
14 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
RayzeBio Propels Forward with $418 Mil Raised to Advance RYZ101
13 Sep 2022 //
BUSINESSWIRE
RayzeBio Advances RYZ101, into Clinical Development for Two Cancer Indications
13 Sep 2022 //
BUSINESSWIRE
PeptiDream and RayzeBio Expand Alliance on Peptide-Radiotherapeutics
09 Aug 2022 //
PRESS RELEASE
RayzeBio Appoints Mary Tagliaferri to its Board of Directors and more
12 Oct 2021 //
BUSINESSWIRE
RayzeBio Expands Leadership Team With Susan Moran, M.D. as Chief Medical Officer
31 Aug 2021 //
BUSINESSWIRE
Nimble Therapeutics and RayzeBio Announce Strategic Research Collaboration
28 Jun 2021 //
BUSINESSWIRE
RayzeBio wants to give radiation therapy new life, and $108M should help
16 Jun 2021 //
FIERCEBIOTECH
RayzeBio Secures $108 Million Series C Financing
15 Jun 2021 //
BUSINESSWIRE
Radiopharmaceuticals platform play RayzeBio bags another megaround
15 Jun 2021 //
ENDPTS
Barely two months after unveiling a new breed of , RayzeBio to $150M
08 Dec 2020 //
ENDPTS
RayzeBio Completes $105M Series B to Advance Radiopharmaceuticals for Cancer
08 Dec 2020 //
BUSINESSWIRE
